Encore Medical develops, manufactures, and markets septal occlusion devices used to close abnormal holes in the heart's atrial septum. Encore delivers these small, implantable devices via catheter to avoid the need for open-heart surgery. The company's primary product treats patent foramen ovale (PFO), a defect linked to strokes, while a secondary product line addresses atrial septal defects (ASD). Encore currently sells exclusively in international markets, including Europe, Latin America, and Southeast Asia, through a network of 11 independent distributors across roughly 20 countries. These distributors purchase devices from Encore and resell them to hospitals and physicians. The growth strategy centers on entering the United States market, where Encore is currently conducting the PerFOrm clinical trial to obtain FDA approval for stroke prevention. The company anticipates that U.S. market access will allow for significantly higher pricing and the establishment of a direct sales force. Additionally, Encore is exploring the use of its PFO devices for migraine relief as a long-term growth opportunity. Success depends on completing clinical trials, securing regulatory approvals, and expanding international distribution.